Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) saw a significant increase in short interest in April. As of April 30th, there was short interest totalling 9,120,000 shares, an increase of 16.0% from the April 15th total of 7,860,000 shares. Currently, 20.0% of the shares of the company are sold short. Based on an average […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) was down 5% during trading on Monday . The stock traded as low as $12.98 and last traded at $13.00. Approximately 319,237 shares were traded during mid-day trading, a decline of 57% from the average daily volume of 742,813 shares. The stock had previously closed at $13.68. […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) dropped 5% on Monday . The company traded as low as $12.98 and last traded at $13.00. Approximately 319,237 shares traded hands during mid-day trading, a decline of 57% from the average daily volume of 742,813 shares. The stock had previously closed at $13.68. Analysts Set New […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) – Stock analysts at Wedbush upped their Q2 2023 earnings estimates for Day One Biopharmaceuticals in a research note issued on Tuesday, May 2nd. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of ($0.58) for the quarter, up from their prior […]
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) announced its quarterly earnings data on Monday. The company reported ($0.59) EPS for the quarter, meeting analysts’ consensus estimates of ($0.59), MarketWatch Earnings reports. Day One Biopharmaceuticals Trading Up 16.7 % Shares of Day One Biopharmaceuticals stock opened at $14.47 on Tuesday. The business’s fifty day simple moving […]